BB
BB Biotech Portfolio holdings
AUM
$3.98B
This Quarter Return
+15.26%
1 Year Return
+15.06%
3 Year Return
+120.36%
5 Year Return
+263.74%
10 Year Return
–
AUM
$3.36B
AUM Growth
+$3.36B
(+8.7%)
Cap. Flow
-$63.8M
Cap. Flow
% of AUM
-1.9%
Top 10 Holdings %
Top 10 Hldgs %
68.61%
Holding
29
New
1
Increased
9
Reduced
13
Closed
2
Top Buys
| 1 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
$43.7M |
| 2 |
RDUS
Radius Health, Inc.
RDUS
|
$39.9M |
| 3 |
CEMP
Cempra, Inc.
CEMP
|
$15.4M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$8.79M |
| 5 |
TSRO
TESARO, Inc.
TSRO
|
$8.61M |
Top Sells
| 1 |
PCYC
PHARMACYCLICS INC
PCYC
|
$89.4M |
| 2 |
Incyte
INCY
|
$23.8M |
| 3 |
CELG
Celgene Corp
CELG
|
$18.4M |
| 4 |
Ionis Pharmaceuticals
IONS
|
$15.7M |
| 5 |
MDVN
MEDIVATION, INC.
MDVN
|
$14.2M |
Sector Composition
| 1 | Healthcare | 82.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $410M | 12.21% |
3,554,298
-160,000
| -4% | -$18.4M |
|
|
2
Ionis Pharmaceuticals
IONS
$6.8B
| $365M | 10.87% |
5,729,426
-247,100
| -4% | -$15.7M |
|
|
3
Incyte
INCY
$16.5B
| $348M | 10.35% |
3,791,867
-260,000
| -6% | -$23.8M |
|
4
Gilead Sciences
GILD
$140B
| $281M | 8.38% |
2,865,596
-80,000
| -3% | -$7.85M |
|
5
Agios Pharmaceuticals
AGIO
$2.19B
| $174M | 5.2% |
1,849,921
-15,000
| -0.8% | -$1.41M |
|
|
MDVN
6
DELISTED
MEDIVATION, INC.
MDVN
| $165M | 4.9% |
1,274,706
-110,000
| -8% | -$14.2M |
|
7
Vertex Pharmaceuticals
VRTX
$100B
| $157M | 4.69% |
1,334,445
-20,000
| -1% | -$2.36M |
|
|
RDUS
8
DELISTED
Radius Health, Inc.
RDUS
| $153M | 4.56% |
3,722,140
+970,000
| +35% | +$39.9M |
|
9
Neurocrine Biosciences
NBIX
$13.8B
| $127M | 3.79% |
3,201,552
+115,000
| +4% | +$4.57M |
|
10
Puma Biotechnology
PBYI
$254M
| $123M | 3.67% |
521,991
| – | – |
|
|
ALXN
11
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $117M | 3.47% |
672,428
| – | – |
|
|
RCPT
12
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $105M | 3.12% |
635,272
-15,909
| -2% | -$2.62M |
|
|
GEVA
13
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
| $100M | 2.98% |
1,025,476
-105,000
| -9% | -$10.2M |
|
14
Halozyme
HALO
$8.56B
| $91.7M | 2.73% |
6,423,370
-402,162
| -6% | -$5.74M |
|
15
Regeneron Pharmaceuticals
REGN
$61.5B
| $89.4M | 2.66% |
198,000
| – | – |
|
|
16
Alnylam Pharmaceuticals
ALNY
$58.5B
| $87.2M | 2.6% |
835,499
+84,211
| +11% | +$8.79M |
|
17
PTC Therapeutics
PTCT
$3.92B
| $71.7M | 2.14% |
1,177,912
-50,000
| -4% | -$3.04M |
|
18
Novavax
NVAX
$1.21B
| $69.9M | 2.08% |
8,450,000
+550,000
| +7% | +$4.55M |
|
|
TTPH
19
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $54.1M | 1.61% |
1,477,114
+175,000
| +13% | +$6.41M |
|
|
TSRO
20
DELISTED
TESARO, Inc.
TSRO
| $49.1M | 1.46% |
854,582
+150,000
| +21% | +$8.61M |
|
|
CLVS
21
DELISTED
Clovis Oncology, Inc.
CLVS
| $45.9M | 1.37% |
618,188
| – | – |
|
|
ICPT
22
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $43.7M | 1.3% |
+155,000
| New | +$43.7M |
|
|
CEMP
23
DELISTED
Cempra, Inc.
CEMP
| $42M | 1.25% |
1,223,000
+448,000
| +58% | +$15.4M |
|
|
INFI
24
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $36.6M | 1.09% |
2,620,737
+300,000
| +13% | +$4.19M |
|
|
IMGN
25
DELISTED
Immunogen Inc
IMGN
| $25.4M | 0.76% |
2,840,816
-400,000
| -12% | -$3.58M |
|